Effects of intravenous immunoglobulin in vivo on abnormally increased tumor necrosis factor-alpha activity in human immunodeficiency virus type 1 infection

被引:18
作者
Aukrust, P
Hestdal, K
Lien, E
Bjerkeli, V
Nordoy, I
Espevik, T
Muller, F
Froland, SS
机构
[1] UNIV OSLO, NATL HOSP,RIKSHOSP,SECT CLIN IMMUNOL & INFECT DIS, MED DEPT A, OSLO, NORWAY
[2] UNIV OSLO, NATL HOSP, RIKSHOSP, INTERNAL MED RES INST, OSLO, NORWAY
[3] UNIV OSLO, NATL HOSP, RIKSHOSP, DEPT PEDIAT RES, OSLO, NORWAY
[4] NORWEGIAN UNIV SCI & TECHNOL, INST CANC RES & MOL BIOL, N-7034 TRONDHEIM, NORWAY
关键词
D O I
10.1086/516510
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The effect of a single bolus injection (0.4 g/kg) of intravenous immunoglobulin (IVIG) on the tumor necrosis factor (TNF) system in human immunodeficiency virus type 1 (HIV-1)-infected patients was investigated. At 140 h after infusion, there was a significant decrease in levels of TNF-alpha and a significant increase in levels of soluble TNF receptors (sTNFR) in both plasma and lipopolysaccharide-stimulated peripheral blood mononuclear cells (PBMC). A rapid (within 1 h) decline in expression of membrane-bound TNF-alpha and p55-TNFR on PBMC persisted throughout the study, In contrast, there was an increased expression of membrane-bound p75-TNFR after 140 h. IVIG administration also resulted in significantly increased numbers of circulating CD4 lymphocytes, correlated with down-regulation of TNF-alpha activity in PBMC supernatants. Thus, down-regulation of the abnormally increased TNF-alpha activity may be achieved by IVIG administration. Studies evaluating the possible therapeutic role of long-term TNF-alpha suppression by IVIG may be warranted in HIV-1-infected patients.
引用
收藏
页码:913 / 923
页数:11
相关论文
共 61 条
[61]  
YAP PL, 1994, CLIN EXP IMMUNOL, V97, P59